GlassScriptPhysician profile
Joseph Isaac Chi
NPI 1760493464
$17,352.48
in general payments reported to CMS, 2019-2025
42 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,715 · 2020: $2,279 · 2021: $2,864 · 2022: $2,866 · 2023: $2,470 · 2024: $2,281 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,545 · Education: $84.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,545.18 |
| Education | $84.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,532.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,393.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,344.95 | 2019-2025 | Jardiance |
| Viiv Healthcare Company | $1,220.53 | 2019-2025 | Dovato |
| Astrazeneca Pharmaceuticals LP | $1,105.63 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,099.42 | 2021-2025 | |
| Abbvie INC. | $947.28 | 2019-2025 | Linzess, Creon, Viberzi |
| Janssen Pharmaceuticals, INC | $868.78 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $863.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $647.64 | 2019-2024 | |
| Glaxosmithkline, LLC. | $575.75 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $571.17 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $533.11 | 2023-2025 | Gemtesa |
| Amgen INC. | $529.02 | 2019-2025 | Repatha, Otezla, Otezla |
| Gilead Sciences, INC. | $475.22 | 2019-2025 | Biktarvy |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.